Cargando…

A prolactin-dependent, metastasising rat mammary carcinoma as a model for endocrine-related tumour dormancy.

In order to study the growth kinetics of breast tumours during long-term hormonal withdrawal, we developed a transplantable, invasive mammary carcinoma EMR-86 that originated in a female WAG/Olac rat bearing a subcutaneously implanted oestrogen pellet (EP). Outgrowth of transplanted tumours occurs o...

Descripción completa

Detalles Bibliográficos
Autores principales: Wijsman, J. H., Cornelisse, C. J., Keijzer, R., van de Velde, C. J., van Dierendonck, J. H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1991
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977640/
https://www.ncbi.nlm.nih.gov/pubmed/1911185
_version_ 1782135305091940352
author Wijsman, J. H.
Cornelisse, C. J.
Keijzer, R.
van de Velde, C. J.
van Dierendonck, J. H.
author_facet Wijsman, J. H.
Cornelisse, C. J.
Keijzer, R.
van de Velde, C. J.
van Dierendonck, J. H.
author_sort Wijsman, J. H.
collection PubMed
description In order to study the growth kinetics of breast tumours during long-term hormonal withdrawal, we developed a transplantable, invasive mammary carcinoma EMR-86 that originated in a female WAG/Olac rat bearing a subcutaneously implanted oestrogen pellet (EP). Outgrowth of transplanted tumours occurs only in the presence of an EP, and metastases are formed in lungs and regional lymph nodes. Subsequent EP removal induces rapid regression. However, tumours do not disappear completely, as small nodules persist. These dormant tumour remnants can be restimulated even after long periods. Because EP-stimulated tumours regressed after treatment with bromocriptine and dormant tumours in non-oestrogenized rats grew out after treatment with perphenazine, prolactin is the major growth-stimulating hormone in this model. Cell kinetics in the growing, regressing and dormant phase were studied by immunocytochemical detection of DNA-incorporated bromodeoxyuridine (BrdUrd) in tissue sections. BrdUrd labelling indices decreased from 21.6 +/- 3.0% to less than 1% within 7 days after EP removal. After prolonged hormonal withdrawal (up to 90 days) BrdUrd-labelled tumour cells could always be demonstrated (range 0.4-0.8%), without a concomitant increase in tumour volume. Additional treatment either with bromocriptine or with ovariectomy could not significantly reduce this residual proliferative activity, as demonstrated by continuous BrdUrd labelling experiments. The results indicate that in vivo dormancy may represent a steady state of cell division and cell loss, rather than an accumulation of cells in a non-cycling G0 state. IMAGES:
format Text
id pubmed-1977640
institution National Center for Biotechnology Information
language English
publishDate 1991
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19776402009-09-10 A prolactin-dependent, metastasising rat mammary carcinoma as a model for endocrine-related tumour dormancy. Wijsman, J. H. Cornelisse, C. J. Keijzer, R. van de Velde, C. J. van Dierendonck, J. H. Br J Cancer Research Article In order to study the growth kinetics of breast tumours during long-term hormonal withdrawal, we developed a transplantable, invasive mammary carcinoma EMR-86 that originated in a female WAG/Olac rat bearing a subcutaneously implanted oestrogen pellet (EP). Outgrowth of transplanted tumours occurs only in the presence of an EP, and metastases are formed in lungs and regional lymph nodes. Subsequent EP removal induces rapid regression. However, tumours do not disappear completely, as small nodules persist. These dormant tumour remnants can be restimulated even after long periods. Because EP-stimulated tumours regressed after treatment with bromocriptine and dormant tumours in non-oestrogenized rats grew out after treatment with perphenazine, prolactin is the major growth-stimulating hormone in this model. Cell kinetics in the growing, regressing and dormant phase were studied by immunocytochemical detection of DNA-incorporated bromodeoxyuridine (BrdUrd) in tissue sections. BrdUrd labelling indices decreased from 21.6 +/- 3.0% to less than 1% within 7 days after EP removal. After prolonged hormonal withdrawal (up to 90 days) BrdUrd-labelled tumour cells could always be demonstrated (range 0.4-0.8%), without a concomitant increase in tumour volume. Additional treatment either with bromocriptine or with ovariectomy could not significantly reduce this residual proliferative activity, as demonstrated by continuous BrdUrd labelling experiments. The results indicate that in vivo dormancy may represent a steady state of cell division and cell loss, rather than an accumulation of cells in a non-cycling G0 state. IMAGES: Nature Publishing Group 1991-09 /pmc/articles/PMC1977640/ /pubmed/1911185 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Wijsman, J. H.
Cornelisse, C. J.
Keijzer, R.
van de Velde, C. J.
van Dierendonck, J. H.
A prolactin-dependent, metastasising rat mammary carcinoma as a model for endocrine-related tumour dormancy.
title A prolactin-dependent, metastasising rat mammary carcinoma as a model for endocrine-related tumour dormancy.
title_full A prolactin-dependent, metastasising rat mammary carcinoma as a model for endocrine-related tumour dormancy.
title_fullStr A prolactin-dependent, metastasising rat mammary carcinoma as a model for endocrine-related tumour dormancy.
title_full_unstemmed A prolactin-dependent, metastasising rat mammary carcinoma as a model for endocrine-related tumour dormancy.
title_short A prolactin-dependent, metastasising rat mammary carcinoma as a model for endocrine-related tumour dormancy.
title_sort prolactin-dependent, metastasising rat mammary carcinoma as a model for endocrine-related tumour dormancy.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977640/
https://www.ncbi.nlm.nih.gov/pubmed/1911185
work_keys_str_mv AT wijsmanjh aprolactindependentmetastasisingratmammarycarcinomaasamodelforendocrinerelatedtumourdormancy
AT cornelissecj aprolactindependentmetastasisingratmammarycarcinomaasamodelforendocrinerelatedtumourdormancy
AT keijzerr aprolactindependentmetastasisingratmammarycarcinomaasamodelforendocrinerelatedtumourdormancy
AT vandeveldecj aprolactindependentmetastasisingratmammarycarcinomaasamodelforendocrinerelatedtumourdormancy
AT vandierendonckjh aprolactindependentmetastasisingratmammarycarcinomaasamodelforendocrinerelatedtumourdormancy
AT wijsmanjh prolactindependentmetastasisingratmammarycarcinomaasamodelforendocrinerelatedtumourdormancy
AT cornelissecj prolactindependentmetastasisingratmammarycarcinomaasamodelforendocrinerelatedtumourdormancy
AT keijzerr prolactindependentmetastasisingratmammarycarcinomaasamodelforendocrinerelatedtumourdormancy
AT vandeveldecj prolactindependentmetastasisingratmammarycarcinomaasamodelforendocrinerelatedtumourdormancy
AT vandierendonckjh prolactindependentmetastasisingratmammarycarcinomaasamodelforendocrinerelatedtumourdormancy